Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. is registering the potential resale of up to 5,483,086 shares of voting common stock for existing investors, not issuing new shares in this transaction and receiving no resale proceeds. These shares may be issued under a June 9, 2026 Series P Non-Convertible Preferred Stock financing and related pre-funded warrants, including up to 4,395,605 Redemption Shares, 32,535 Commencement Shares, and up to 1,054,946 Dividend Shares based on an 8% annual dividend over three years using a $0.546 Floor Price.
The preferred financing raised $2 million through 240 Series P shares with 8% dividends payable in cash or stock subject to an Equity Condition, and is linked to a $40 million equity line of credit with C/M Capital. As of July 10, 2026, common shares outstanding were 4,910,402; if all registered shares were issued, they would represent over 52.76% of the then-outstanding common stock, creating substantial dilution and potential selling pressure. The company also discloses restrictive covenants in the preferred agreements that can limit additional financings and details anti-takeover and capital structure terms.
Jaguar Health, Inc. registers up to 40,874,552 shares of common stock for resale by C/M Capital Master Fund, LP under a committed equity line of up to $40 million. Jaguar is not selling shares in this offering and will not receive proceeds from stockholder resales, though it may receive cash from future share sales to C/M Capital under the purchase agreement.
The equity line allows Jaguar, at its discretion and subject to conditions, to direct C/M Capital to buy shares through fixed and VWAP-based purchases, generally at a 5% discount to market, with a floor price of $1.10 and a 4.99% beneficial ownership cap. Shares outstanding were 4,910,402 as of July 10 2026; if all registered shares were issued, they would represent over 89% of that figure, materially diluting existing holders.
Jaguar intends to use any proceeds from sales to C/M Capital for working capital and general corporate purposes, including potential redemption of Series P Preferred Stock. The company also highlights extensive gastrointestinal drug-development programs centered on crofelemer, including orphan and rare disease indications such as MVID and SBS-IF.
Jaguar Health, Inc. is calling a special meeting on September 4, 2026 to seek stockholder approval for several equity-related actions. Proposal 1 would approve, for Nasdaq Listing Rule 5635(d) purposes, issuing common shares from time to time upon exchange of 889.28 outstanding shares of Series Q Perpetual Preferred Stock, which were issued in exchange for reductions of two $12 million royalty interests held by Uptown Capital and Streeterville Capital. Each Series Q share has a $25,000 stated value and exchanges at a variable price based on recent Nasdaq closing prices, so full exchange could result in a very large increase in common shares outstanding and materially dilute existing holders.
Proposal 2 would reprice investor warrants on 60,781 common shares from exercise prices of $35.00–$266.44 down to $1.00 per share, with a shortened post-approval exercise window and cashless exercise, and recognizes that these warrants, together with related Series O dividend and placement-agent warrants, could result in up to 745,354 new shares, about 13.3% of common stock as of July 6, 2026. Proposal 3 would amend the 2014 Stock Incentive Plan so that the share pool equals 14% of fully diluted common shares as of September 30, 2026, up from 10,591 shares currently available (about 0.17% fully diluted). Proposal 4 would permit adjournments to gather additional proxies. Record-date voting power is 4,857,211 common shares and 889.28 Series Q shares, with each Series Q carrying 6,890 votes but subject to a 9.99% Voting Cap.
Jaguar Health, Inc. is registering 41,000,000 shares of common stock for potential resale by C/M Capital Master Fund, LP under a committed equity financing structure. This consists of up to 40,000,000 Purchase Shares issuable under a June 9, 2026 common stock purchase agreement plus up to 1,000,000 Commitment Shares issued as consideration.
The company will not receive proceeds from resale of these shares, but may raise up to $40 million in gross proceeds from selling shares to C/M Capital over time, subject to pricing formulas, an $1.10 floor price, ownership caps and other conditions. Shares outstanding were 4,910,402 as of July 10, 2026; issuing all 41,000,000 registered shares would represent over 89.3% of that total, creating significant potential dilution.
Jaguar develops crofelemer-based therapies for complex gastrointestinal and intestinal failure conditions, with FDA-approved Mytesi and multiple orphan-designated programs. Recent financings include a $2.0 million private placement of Series P preferred stock and a fully converted Series O preferred stock dividend, both adding to the capital structure described in this prospectus.
Jaguar Health, Inc. is registering for resale up to 40,800,000 shares of common stock held or issuable to C/M Capital Master Fund, LP under a committed equity line. Jaguar is not selling shares in this prospectus and will receive no proceeds from the selling stockholder’s resales.
Under a June 2026 purchase agreement, Jaguar may sell up to $40 million of stock to C/M Capital at its discretion, subject to a floor price of $1.10, daily caps and a 4.99% beneficial ownership limit. As of July 10 2026, Jaguar had 4,910,402 common shares outstanding; if all 40,800,000 registered shares were issued, they would exceed 89.3% of then-outstanding shares, implying substantial potential dilution.
Recent financings include a January 2026 US license with Future Pak providing $16.0 million upfront plus potential $2.0 million additional and up to $20 million in milestones, a $2.0 million Series P preferred stock private placement, and conversion of Series O preferred into common stock. Jaguar’s lead drug crofelemer has FDA approval for HIV-related diarrhea and holds multiple orphan drug designations, with advanced development in rare intestinal failure disorders MVID and SBS-IF.
Jaguar Health has filed a resale registration covering up to 5,522,551 shares of common stock, all to be sold from time to time by selling stockholders under prior financing arrangements. The company is not selling shares in this offering and will not receive proceeds from these resales.
The registered shares are tied mainly to its June 2026 financing of 240 shares of Series P Preferred Stock for $2 million, including potential redemption, warrant and dividend shares linked to an 8% annual dividend. As of July 10, 2026, common shares outstanding were 4,910,402; if all registered shares were issued, they would represent more than 52.93% of the outstanding common stock, indicating substantial potential dilution and overhang.
Jaguar also describes a committed $40 million equity line of credit and a pipeline centered on crofelemer for HIV-related diarrhea, cancer therapy-related diarrhea and ultra-rare intestinal failure conditions, where crofelemer carries multiple Orphan Drug Designations in the US and EU.
Jaguar Health, through its wholly owned subsidiary Napo Pharmaceuticals, has entered into a new manufacturing and supply agreement with Alivus Life Sciences dated July 9, 2026. Under this 2026 Agreement, Alivus will continue to manufacture crofelemer for use in Mytesi and other crofelemer-based human and animal products for Napo, its affiliates, or third parties designated by Napo.
The 2026 Agreement includes Napo’s commitment to purchase minimum quantities of crofelemer, with potential shortfall payments, subject to quarterly caps unless capacity is expanded at Napo’s written request. It runs through March 31, 2029, with options for successive renewals of at least two years, and allows termination for convenience with 12 months’ notice or for specified events, including uncured material breach, insolvency scenarios, regulatory withdrawal of crofelemer products, or chronic failure to supply. If an Insolvency Event occurs under a related license agreement, Napo’s rights and obligations under the 2026 Agreement for crofelemer manufacturing would be assigned to Woodward Specialty LLC.
Jaguar Health completed the previously announced conversion of its Series O Convertible Preferred Stock into common stock. Effective June 25, 2026, each share of Series O Preferred Stock converted into 3.209 shares of common stock.
Immediately after the conversion, Jaguar Health had 4,857,211 shares of common stock issued and outstanding. Holders of Eligible Warrants can receive up to 839,000 shares of common stock upon exercise, consisting of 68,593 warrant shares and 770,407 conversion shares linked to the Series O Preferred Stock dividend structure.